Table 1 Age, menstrual phase data and hormonal contraception (HC) formulation

Normal_1

37

5

no

F

49

0.5

5.7

Normal_2

20

14

yes

Tri-Legest Fe

-

32

1.5

9.6

Normal_3

30

13

no

F

32

<0.01

3.6

Normal_4

44

19

yes

Ortho Tri-Cyclen Lo

-

432

0.4

5.1

Normal_5

40

9

no

F

28

0.5

5.6

Normal_6

27

27

yes

Nuvaring

-

N/A

N/A

N/A

Normal_7

23

29

no

L

71

6.1

3.2

Normal_8

27

25

no

L

82

3.7

4.9

Normal_9

39

4

no

F

198

0.1

N/A

Normal_10

38

26

no

L

131

21.4

3

Normal_11

22

28

yes

Necon1-35

-

36

1.1

0.2

Normal_12

45

27

no

L

47

2.9

3.6

Normal_13

19

7

yes

Zenchent

-

26

0.7

2.4

Normal_14

36

2

no

F

53

0.6

4.4

Normal_15

26

9

no

F

43

0.9

10.3

Normal_16

22

29

no

L

136

12.4

5.3

Normal_17

46

6

no

F

121

0.5

5.6

Normal_18

31

29

yes

LoEstrin 24

-

34

1.1

2

Normal_19

29

2

no

F

61

0.6

7.9

Normal_20

21

7

no

F

43

0.3

3.5

HC type

Tri-Legest Fe

1 mg norethindrone acetate and 20 mcg ethinyl estradiol × 1 week; 1 mg norethindrone acetate and 30 mcg ethinyl estradiol × 1 week; 1 mg norethindrone acetate and 35 mcg ethinyl estradiol × 1 week

Ortho Tri-Cyclen Lo

0.180 mg of norgestimate and 0.025 mg ethinyl estradiol × 1 week; 0.215 mg of norgestimate and 0.025 mg ethinyl estradiol × 1 week; 0.250 mg of norgestimate and 0.025 mg of ethinyl estradiol × 1 week

Nuvaring

Necon1-35

Norethindrone 1 mg, ethinyl estradiol 35 mcg

Zenchent

0.4 mg norethindrone and 0.035 mg ethinyl estradiol

LoEstrin 24

1 mg norethindrone acetate and 20 mcg ethinyl estradiol